Press Releases April 7, 2026 02:00 AM

Pharming Group to participate in April investor conferences

Pharming Group to present at two key April 2026 investor conferences.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
PHAR

Pharming Group N.V., a global biopharmaceutical company, announced that its management will participate and present at the 25th Annual Needham Virtual Healthcare Conference and the Van Lanschot Kempen Life Sciences Conference in April 2026. The presentations aim to update investors on company developments and facilitate meetings with investors and analysts.

Pharming Group to participate in April investor conferences
PHAR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Pharming’s CEO and CMO will deliver a presentation at the Needham Healthcare Conference on April 13, 2026.
  • The company will also participate in the Van Lanschot Kempen Life Sciences Conference on April 15, 2026 in Amsterdam.
  • Pharming is a global biopharmaceutical company focused on rare and life-threatening diseases, with listings on Euronext Amsterdam and NASDAQ and significant U.S. employee presence.

Leiden, the Netherlands, April 7, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of April:

  • 25th Annual Needham Virtual Healthcare Conference, April 13, 2026
    Fabrice Chouraqui, Chief Executive Officer, and Anurag Relan, Chief Medical Officer, will present on Monday, April 13 at 08:45 am ET/14:45 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” and “News” sections of Pharming’s website.
  • Van Lanschot Kempen Life Sciences Conference 2026, Amsterdam, NL, April 15, 2026

For more information about these conferences, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at [email protected] or your Needham or Van Lanschot Kempen representative.

About Pharming Group N.V.
Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.

For more information, visit www.pharming.com and find us on LinkedIn.

For further public information, contact:
Investor Relations
Michael Levitan, VP Investor Relations & Corporate Communications
T: +1 (908) 705 1696
E: [email protected]

Media Relations
Global: Saskia Mehring, Corporate Communications Manager
T: +31 6 28 32 60 41
E: [email protected]

U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)
T: +1 (917) 882-9038

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)
T: +31 6 53 81 64 27

Attachment

  • Pharming attending Investor Conferences April 2026_EN_07APR26

Risks

  • The announcement is primarily about conference participation without updates on clinical or commercial progress, limiting immediate impact on stock performance.
  • Biopharmaceutical sector risks including potential regulatory approvals and clinical trial outcomes impacting investor sentiment.
  • Global and cross-border risks due to Pharming’s multinational operations, including currency fluctuations and geopolitical factors impacting business.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026